|
|
||||||||
The Journal of Immunology, Vol 156, Issue 10 3660-3667, Copyright © 1996 by American Association of Immunologists
ARTICLES |
BB Hashemi, JP Slattery, D Holowka and B Baird
School of Applied and Engineering Physics, Cornell University, Ithaca, NY 14853, USA.
We have investigated the functional advantage of surface-attached ligands for TCR-mediated cell activation with flow cytometric measurements of cytoplasmic Ca2+ changes in T cells after aggregation of TCR by soluble and bead-attached mAb. Conjugation of HPB-ALL human leukemia cells with cell-sized beads coated with anti-TCR mAb causes a stronger, more sustained Ca2+ response than that produced by the soluble form of the same mAb. Addition of a large excess of the soluble mAb subsequent to stimulation with the beads causes a marked reduction in the response of the bead-conjugated cells, but only limited disruption of the conjugates. Free (nonconjugated) cells, sampled simultaneously in this mixture, respond to the soluble mAb with a transient Ca2+ increase that declines with the same kinetics as the bead-conjugated cells after addition of the soluble mAb. Fab fragments of the anti-TCR mAb cause a similar reduction in the response of the bead-conjugated cells, and they do not stimulate free cells. Following the Fab-mediated decline in cytoplasmic Ca2+ of conjugated cells to near-baseline concentrations, the addition of a second, noncompetitive, anti-TCR mab causes a Ca2+ response that is substantially reduced in magnitude compared with that for the free cells. The results indicate that soluble and surface-attached ligands cause TCR-specific desensitization of the Ca2+ response. Surface-attached ligands are more effective than soluble ligands in sustaining signaling in T cells at least in part because they facilitate steady association and/or reassociation of TCR into the bound state in the surface contact area.
This article has been cited by other articles:
![]() |
F. Andris, S. Denanglaire, F. de Mattia, J. Urbain, and O. Leo Naive T Cells Are Resistant to Anergy Induction by Anti-CD3 Antibodies J. Immunol., September 1, 2004; 173(5): 3201 - 3208. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. F. Hanna, C. L. Kerr, J. H. Shaper, and W. W. Wright Lewis X-Containing Neoglycoproteins Mimic the Intrinsic Ability of Zona Pellucida Glycoprotein ZP3 to Induce the Acrosome Reaction in Capacitated Mouse Sperm Biol Reprod, September 1, 2004; 71(3): 778 - 789. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Borovsky, G. Mishan-Eisenberg, E. Yaniv, and J. Rachmilewitz Serial Triggering of T Cell Receptors Results in Incremental Accumulation of Signaling Intermediates J. Biol. Chem., June 7, 2002; 277(24): 21529 - 21536. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Pasare, P. Mukherjee, A. Verhoef, P. Bansal, S. K. Mendiratta, A. George, J. R. Lamb, S. Rath, and V. Bal T cells in mice expressing a transgenic human TCR{beta} chain get positively selected but cannot be activated in the periphery by signaling through TCR Int. Immunol., January 1, 2001; 13(1): 53 - 62. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Harder and M. Kuhn Selective Accumulation of Raft-Associated Membrane Protein Lat in T Cell Receptor Signaling Assemblies J. Cell Biol., October 16, 2000; 151(2): 199 - 208. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Holowka, E. Sheets, and B Baird Interactions between Fc(epsilon)RI and lipid raft components are regulated by the actin cytoskeleton J. Cell Sci., January 3, 2000; 113(6): 1009 - 1019. [Abstract] [PDF] |
||||
![]() |
B. B. HASHEMI, J. E. PENKALA, C. VENS, H. HULS, M. CUBBAGE, and C. F. SAMS T cell activation responses are differentially regulated during clinorotation and in spaceflight FASEB J, November 1, 1999; 13(14): 2071 - 2082. [Abstract] [Full Text] |
||||
![]() |
N. N. Berg, L. G. Puente, W. Dawicki, and H. L. Ostergaard Sustained TCR Signaling Is Required for Mitogen-Activated Protein Kinase Activation and Degranulation by Cytotoxic T Lymphocytes J. Immunol., September 15, 1998; 161(6): 2919 - 2924. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |